Breathe Well Live Well
|
Merck's stock falls after disclosing government probe into asthma drug pricing
MarketWatch Merck & Co. Inc.'s stock dropped 1.5% in midday trade Friday, after the drug maker disclosed in a filing late Thursday that it had received a civil investigative demand from the U.S. Attorney's office. The demand requests information related to the … |
View full post on asthma – Google News
|
In the Treatment of Asthma, Merck's Singulair Accounts for More Than a Quarter …
MarketWatch (press release) Analysis of US patient-level claims data from Treatment Algorithms in Asthma also finds that more than half of newly diagnosed asthma patients that move to the second line of therapy within a year of diagnosis are treated with Singulair. … |
View full post on asthma – Google News